The Timing of Liver Transplantation Following Downstaging: Wait of Not to Wait?

Basit Öğe Kaydı
dc.authoridErsan, Veysel/0000-0002-1510-0288
dc.authoridYilmaz, Sezai/0000-0002-8044-0297;
dc.authorwosidErsan, Veysel/AAB-9595-2020
dc.authorwosidYilmaz, Sezai/ABI-2323-2020
dc.authorwosidBarut, Bora/ABD-9882-2020
dc.contributor.authorErsan, Veysel
dc.contributor.authorBarut, Bora
dc.contributor.authorYilmaz, Sezai
dc.date.accessioned2024-08-04T20:48:50Z
dc.date.available2024-08-04T20:48:50Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose HCC is a complex disease that is diagnosed in advanced stage and on the background of cirrhosis. Locoregional therapies provide sufficient downstaging to enable patients suitable for radical procedures such liver transplantation. However, the interval between locoregional therapies and definitive therapy is still controversial. We performed a review of literature to evaluate the role of waiting period between locoregional therapies and liver transplantation or resection from the perspective of cure and recurrence rates. Methods Thorough literature search was performed to evaluate the role of locoregional therapy and the interval to definitive therapies for the treatment of hepatocellular cancer. Results Usually, small tumors with lower tumor burden, in other words, tumors within Milan criteria, can be transplanted with an acceptable overall and disease-free survival. However, treating patients with locally advanced tumors is currently a matter of extensive research. Currently, locoregional therapies are applied to downstage the patients. However, the duration of waiting is a crucial point that needs further research. There is a consensus that the waiting interval between down-staging and transplantation should be no less than 3 months. This is important for selection of favorable tumor biology as well as from the point of antitumor immune response. Conclusion Currently, there are no surrogate markers for surveillance of response to locoregional therapies as well as the antitumor immune response that develops as a result of down-staging.en_US
dc.identifier.doi10.1007/s12029-020-00491-z
dc.identifier.endpage1156en_US
dc.identifier.issn1941-6628
dc.identifier.issn1941-6636
dc.identifier.issue4en_US
dc.identifier.pmid32856230en_US
dc.identifier.scopus2-s2.0-85089891572en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1152en_US
dc.identifier.urihttps://doi.org/10.1007/s12029-020-00491-z
dc.identifier.urihttps://hdl.handle.net/11616/99490
dc.identifier.volume51en_US
dc.identifier.wosWOS:000565037300001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Gastrointestinal Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLocoregional therapyen_US
dc.subjectHepatocellular carcinomaen_US
dc.subjectDown-stagingen_US
dc.subjectAntitumor immune responseen_US
dc.subjectTumor microenvironmenten_US
dc.titleThe Timing of Liver Transplantation Following Downstaging: Wait of Not to Wait?en_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu